Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $84.5 million.

  • Rhythm Pharmaceuticals' Accumulated Expenses rose 5412.52% to $84.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.5 million, marking a year-over-year increase of 5412.52%. This contributed to the annual value of $62.7 million for FY2024, which is 2982.89% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Accumulated Expenses stood at $84.5 million for Q3 2025, which was up 5412.52% from $69.2 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Accumulated Expenses ranged from a high of $84.5 million in Q3 2025 and a low of $7.2 million during Q1 2021
  • Over the past 5 years, Rhythm Pharmaceuticals' median Accumulated Expenses value was $35.7 million (recorded in 2023), while the average stood at $40.5 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 3659.66% in 2021, then soared by 25243.36% in 2022.
  • Rhythm Pharmaceuticals' Accumulated Expenses (Quarter) stood at $30.1 million in 2021, then grew by 9.34% to $32.9 million in 2022, then skyrocketed by 46.72% to $48.3 million in 2023, then increased by 29.83% to $62.7 million in 2024, then surged by 34.79% to $84.5 million in 2025.
  • Its Accumulated Expenses stands at $84.5 million for Q3 2025, versus $69.2 million for Q2 2025 and $59.3 million for Q1 2025.